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Malate dehydrogenases (MDHs) sustain tumor growth and carbon metabolism by pathogens
including Plasmodium falciparum. However, clinical success of MDH inhibitors is absent, as
current small molecule approaches targeting the active site are unselective. The presence of
an allosteric binding site at oligomeric interface allows the development of more specific
inhibitors. To this end we performed a differential NMR-based screening of 1500 fragments
to identify fragments that bind at the oligomeric interface. Subsequent biophysical and bio-
chemical experiments of an identified fragment indicate an allosteric mechanism of 4-(3,4-
difluorophenyl) thiazol-2-amine (4DT) inhibition by impacting the formation of the active site
loop, located >30 Å from the 4DT binding site. Further characterization of the more tractable
homolog 4-phenylthiazol-2-amine (4PA) and 16 other derivatives are also reported.
These data pave the way for downstream development of more selective molecules by
utilizing the oligomeric interfaces showing higher species sequence divergence than the
MDH active site.
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Malate dehydrogenases are a group of multimericenzymes, typically self-organized as dimers or tetra-mers, that reversibly catalyze the oxidation of malate
to oxaloacetate using the reduction of NAD+ to NADH as a
cofactor1. Based on subcellular localization, eukaryotic cells
possess two isoforms (cytoplasmic and mitochondrial), though
yeasts possess a third in glyoxysomes2. While cytoplasmic
malate dehydrogenase (MDH) supports the malate–aspartate
shuttle—allowing reducing equivalents to pass through the
inner mitochondrial membrane—mitochondrial MDH is
involved in NADH and citrate production to support the
electron-transport chain within the TCA cycle1. Under phy-
siological conditions, MDH regulates essential biochemical
pathways related to energy metabolisms, like gluconeogenesis
and the fatty acid cycle, and cell division. In many forms of
breast cancer, the biomass growth depends on NAD regenera-
tion by lactate dehydrogenase, an oxidoreductase enzyme
structurally related to MDH. Thus, an high LDH expression
represents a diagnostic hallmark in cancer3. However, in the
presence of LDH antagonists like oxamate, cancer cells adopt
an evasion mechanism involving MDH which is recruited in
order to support glycolysis in the absence of oxygen and pro-
duction of NAD4. This suggests that a tailored therapy aimed at
modulating this supportive role of MDH within the glycolysis
could hinder the abnormal energetic need required by cancer
for proliferation5. Several antagonists are reported for one of
the two MDH isoforms or both. For instance, elevated
expression of HsMDH2 is associated with prostate cancer
development and chemotherapy resistance6 and, to date, 5-
benzylpaullones remains the most potent compound for selec-
tive inhibition of this specific isoform, as exemplified by inhi-
bitor 4k7. Dual target inhibition becomes particularly effective
when both HsMDH1 and HsMDH2 are overexpressed in
NSCLC patients8. In this regard, trimethylpentane derivatives
were identified and characterized as potent HsMDH1/MDH2
dual-target inhibitors9. Specifically, compound 16c demon-
strated the highest efficacy in a mouse xenograft assay and
inhibited mitochondrial respiration through a competitive
inhibition mechanism with NAD.
Given the ubiquity of the dinucleotide binding domain
(Rossman fold) in NADH binding enzymes10 and its presence in
155 reviewed enzymatic activities within human cells (Interpro
ID: IPR03629111), it is perhaps not surprising that many of these
antagonists possess cytotoxic effects. In this regard, non-specific
MDH inhibitors are reported in the literature. For instance, while
rottlerin, quercetin, and staurosporine aglycone were originally
designed for PKCδ/PRAK, PI3-K/GLUT2, and PKC/PKA they
also inhibit MDH with an IC50 of 0.7, 6.0, and 8.0 μM,
respectively12. Furthermore, 3 h exposure to 5 μM of the alkaloid
staurosporine aglycone led to an 80% decrease in cell viability via
caspase activation mechanisms and oxidative DNA damage
through reactive oxygen species formation13,14.
In terms of infectious diseases, both cytoplasmic and mito-
chondrial MDH have also been found to be anthelmintic tar-
gets: Mebendazole hinders the polymerization of microtubules,
thus blocking cell divisions. Like the other three known
anthelmintics (i.e., Albendazole, Parbendazole, and Thia-
bendazole), it has been reported that it displays significant
inhibitory effects for both MDH and LDH15,16. In a similar
fashion, MDH was also suggested to be the drug target of
miconazole, econazole, and sulconazole, originally designed
and approved as antifungal medication for local use with
unprecedented inhibitory activity (95–99% motility inhibition
at 30 μM for 48 h)17. Considering that the mechanism of action
of these compounds is based on the inhibition of the fungal
enzyme 14α-sterol demethylase, these data suggest that they
could be repurposed also as MDH inhibitors18. This evidence
highlight not only the need to discover selective MDH chemical
antagonists—leading to more effective treatments—but also
that such antagonists should select between the highly con-
served active sites of other NAD-dependent enzymes.
Lunev and Batista assessed the role of oligomeric surfaces in
regulating the assembly of PfMDH—the deadliest causative agent
of Malaria among the five species that affect humans19—showing
by in vivo and in vitro modulation of its activity that oligomeric
surfaces might be targeted for the treatment of diseases related to
MDH function20,21. Gossypol, a phenol derivative from the cot-
tonseed plant, is the most potent PfMDH inhibitor with an IC50
of 2.03 ± 0.80 μM22, followed by oxamic acid derivatives22.
Interestingly, oxamic acid derivatives display inhibitory effects
also for PfLDH, a confirmed antimalaria drug target23. PfMDH
and PfLDH complement each other to maintain a constant
production of NAD, necessary for the oxidation of glucose and
biosynthesis of ATP during glycolysis24 as the treatment of cul-
tures with gossypol caused the reduction of PfLDH expression
with concomitant overexpression of PfMDH. Thereby, the design
of dual-target inhibitors of both enzymes has been proposed.
However, compounds synthesized as potential chemotherapeutics
for Malaria suffer from the same low selectivity as those for
cancer. The inhibitors 5–7 are also active against both the
mammalian mitochondria and cytosolic malate dehydrogenases
since the naphthalene ring mimics the planarity of the adenine of
NAD and the negative charge from the conjugated oxamate
moiety interacted with two highly conserved arginine residues
which secure malate in the catalytic pocket25. Even gossypol
exhibits side effects that may limit its use as an antimalarial
compound as it has been initially characterized as a promising
male oral contraceptive but later failed due to hypokalemia and
the irreversibility of its contraceptive effect26. In contrast, much is
known about small molecules inhibiting PfLDH, such as azole-
based compounds27, quinoline derivatives28, tricyclic guanidine
derivatives29, chloroquine30, and the aforementioned oxamic acid
derivatives22,31.
In summary, while inhibition of MDH presents a major
opportunity in both cancer and infectious diseases the currently
available modulating molecules all target the NADH binding
site, resulting in reduced off-target effects and greatly limiting
their clinical usefulness. To address this, we have systematically
searched for small molecule fragments that would bind to the
oligomeric interface of an exemplar MDH, rather than the
active NADH binding site. In support of this approach, an
allosteric cryptic site of MDH has been recently proposed32.
Our search using saturation transfer difference nuclear mag-
netic resonance (STD-NMR) identified a fragment (4-(3,4-
difluorophenyl) thiazol-2-amine; 4DT) for which binding has
been orthogonally validated using microscale thermophoresis
and a thermal shift assay. We have confirmed the binding site
as distant from the active site using X-ray crystallography and
show, as hypothesized by us, that such molecules binding at the
oligomeric interface inhibit MDH activity. In addition, we
present biochemical competition assays of a library of 16 4DT
derivatives, which are also screened in an activity assay. Small-
angle X-ray scattering assayed the oligomeric state of the pro-
tein in solution in the presence of 4DT derivatives, demon-
strating that complete disruption of the oligomeric state is not
essential for the measured effects. Finally, kinetic data to sup-
port the proposed allosteric inhibitory nature of the scaffold 4-
phenylthiazol-2-amine is presented. This identification of an
allosteric pocket opens the opportunity to overcome the low
selectivity associated with substrate or cofactor analogs and
presents a starting point for the future development of specific
MDH inhibitors.
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Results
Initial identification and orthogonal validation of the fragment
hit. PfMDH WT and V190W were cloned, expressed, and pur-
ified with minor modifications20,33. V190W PfMDH has been
shown to possess a perturbed oligomeric interface resulting in a
breakdown of the wild-type tetrameric assembly into soluble
dimers with the oligomeric interface being solvent exposed20.
Totally, 20 mM Tris-base was used in place of 100 mM citrate at
the same pH (7.4) and ionic strength (400 mM NaCl). We per-
formed STD-NMR against a library of 1500 fragments from the
Maybridge Ro3 diversity fragment library. Initially, 16 fragments
were identified to bind to WT PfMDH and 37 to V190W PfMDH.
Comparison of the results reveals that seven fragments binding to
V190W PfMDH are also bound to WT PfMDH—suggesting 30
potential candidates interacting with the oligomeric interface.
Subsequent ranking of these 30 candidates was driven by the
principle that the nearer the ligand protons are to the protein, the
more likely become highly saturated. Consequently, the signals
displaying the strongest intensity in the mono-dimensional STD
spectrum reflect the proximity of the ligand to the protein
surface34,35. Of the 30 fragments, only 4DT showed a high-
intensity peak in the aromatic region between 6 and 8 ppm and a
weaker intensity peak at 2 ppm (Fig. 1a). Since STD-NMR tells
whether or not a fragment binds and in what orientation in the
binding pocket, this was interpreted as indicating that 4DT binds
to dimeric V190W PfMDH at a position buried in the WT
PfMDH and that the remaining compounds may make a non-
specific interaction with the newly exposed tryptophan at position
190. An MST assay orthogonally validated fragment binding with
Kd of 99.0 ± 1.7 μM (Fig. 1b) against PfMDH. During the
experiment, we observed that saturating concentrations of the
compound blenched the fluorescence signal. Nevertheless, no
protein aggregates were detected in either of the capillaries.
Moreover, 4DT also possesses drug-like properties as shown by
the analysis of SwissADMET (Fig. 1c). Finally, 4DT (Tm= 56 ±
0.17 °C) destabilizes PfMDH with a measured ΔTm of −2.00 ±
0.17 °C with no statistical difference from the control group
treated with DMSO (Tm= 58 ± 0.33 °C) (Fig. 1d, Supplementary
Table 7).
4-(3,4-difluorophenyl) thiazol-2-amine binds at the oligomeric
interface. In order to elucidate the binding site of 4DT, crystals of
PfMDH were soaked in the presence of 2.5 mM of compound,
and diffraction data were collected at 2.1 Å resolution (Table 1).
The reservoir solution was supplemented with 0.5 mM NADH.
The ternary complex with 4DT and NADH is deposited in the
PDB under the accession code 6R8G. Based on the presence of
Fig. 1 Biophysical characterization of 4DT. a STD-NMR, b MST validation with fluorescently labeled WT PfMDH, and c drug-likeness profile from
SwissADME61. The pink area represents the optimal range for each property (lipophilicity: XLOGP3 between −0.7 and +5.0, size: MW between 150 and
500 g/mol, polarity: TPSA between 20 and 130 Å2, solubility: log S not higher than 6, saturation: fraction of carbons in the sp3 hybridization not less than
0.25, and flexibility: no more than 9 rotatable bonds. d Thermal destabilization of PfMDH in presence of 4DT (red lines) and control group (green lines) as
measured by TSA experiments. RFU relative fluorescence units. Data are represented as mean ± SEM (n= 3 biologically independent experiments).
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unambiguous electron density one molecule of NADH and four
molecules of 4DT were modeled in the dinucleotide binding site
of chain D and at the AC, BD interfaces, respectively. At the AC
interface, 4DT occupies a total surface area of 307 Å2, 60% of
which consists of contacts with chain A and the remaining 40%
with chain C. The fluoride atoms face the β7 sheet, while the
amino group and thiazole ring flank the β10–12 sheets from chain
A. On the opposite side, these functional groups contact the loops
K160–D165 and N188–P192 from chain C (Fig. 2b). PISA ana-
lysis quantified the ΔiG P value as equal to −1 for all four
molecules, suggesting the interface surface to be interaction-
specific rather than an artifact due to crystal contacts. Further-
more, it shows that the binding site mainly consists of hydro-
phobic contacts. Interestingly, the fragment binds next to V190
whose mutation to tryptophan interferes with the protein native
assembly20. As shown in Fig. 2a, the benzene and the thiazolyl
moieties at the AC interface form a T-shaped π stacking inter-
action with F284. Further visual inspection of the pocket revealed
a wide network of van der Waals interactions between the 4DT
sulfur atom and V161, M200, F195, F284 side chains and between
the meta fluorine atom and the side chains of V187, N188, and
V169. Moreover, the substitution pattern around the benzene
ring shows that only the fluorine atom in the meta position
possesses a higher score (2.0) than the one in para (0.5). This
could be related to the fact that the C chain interface provides two
apolar contacts with V190, N188 plus one with V169 of the A
chain while at the para position we observed only one between
T271 and fluorine. Therefore, a replacement of fluorine with an
atom or functional group with a greater Van der Walls radius
specifically in meta position could benefit from more steric
contacts with the oligomeric interface (Fig. 2c).
Structural rearrangements related to 4-(3,4-difluorophenyl)
thiazol-2-amine binding. The binding of 4DT did not impact the
overall tetrameric structure of WT PfMDH when compared with
the apo form (0.47 Å RMSD). Nevertheless, a closer inspection of
both the AD and BC interfaces revealed substantial rearrange-
ments of L250 (3.52 Å, CD1), V282 (3.10 Å, CG2), and K273
(2.84 Å, CE) side-chain positions to accommodate 4DT in the
binding site (Fig. 3b–e). Moreover, we observed further Cα shifts
in the 177–174 loop near the NAD binding site (Fig. 3a). In
addition, the atomic coordinates of the loop R75-I87 located
between helices α3 and β4 sheet of the catalytic site of chains A–C
were omitted due to a lack of electron density, caused by an
increase in local structural flexibility. Similarly, disordered active
site loops were observed in the NADH bound form and no
electron density is observed for residues Q80–L90. Finally, a
structural comparison between the ligand and citrate bound
forms (Fig. 3f) reveals an active site loop in a solvent-exposed
open conformation. In contrast, when PfMDH interacts with
citrate the active site loop secures the molecule through ionic
interactions with arginines R150 and R81 which both confer
substrate specificity. This observation was noted also in Escher-
ichia coli MDH36. Following this loop motion of approximately
80°, the R81 guanidine group loses an ionic contact with the
carboxylic functional group of the citrate. Taken together, these
data corroborate the existence of an allosteric site in PfMDH
located at the AD, BC interfaces for the potential development of
modulators that do not affect human isoforms as described by
Botros et al.32.
Sequence and interface analysis of the binding site. To explore
the sequence identities at the 4DT and orthosteric binding
sites, we have performed multiple sequence alignment with
ClustalW37 of three MDHs from pathogenic microorganisms
and the two human isoforms. PfLDH was included in the
analysis. This resulted in 97% sequence coverage (Supple-
mentary Figs. 1 and 6) with Homo sapiens accounting for the
Table 1 Data collection and refinement statistics.
6R8G 6Y91
Data collection
Space group P212121 P212121
Cell dimensions




a, b, g (°) 90, 90, 90 90, 90, 90
Completeness (%) 99.8 (99.4) 99.7 (96.6)
Multiplicity 14.2 16.8
I/σ(I) 14.3 (2.0) 9.3 (2.1)
Rmerge 0.19 (0.91) 0.29 (0.99)
Refinement
Resolution (Å) 2.0 2.5










RMSD bond lengths (Å) 0.010 0.008
RMSD bond angles (°) 1.550 1.323
Values in parenthesis refer to the high-resolution shell (2.23–2.10Å). †Rmerge =, where Ii(hkl) is
the mean intensity of the ith observation of symmetry-related reflections hkl. ‡Rcryst =, where
Fcalc is the calculated protein structure factor from the atomic model (Rfree was calculated with a
randomly selected 5% of the reflections).
Fig. 2 4DT bind to an allosteric pocket distinct from the substrate- and
NADH-binding sites. a Left: an overview of WT PfMDH tetramer with
bound 4DT (pink color, sticks). Monomers are displayed as surfaces. Right:
close-up of the binding site of 4DT showing interactions with the protein
residues (magenta and green sticks). van der Waals, π-stacking, and other
interactions are indicated in brown, orange, and green dotted lines,
respectively. b Secondary structure representation of the AC interface
containing two molecules of 4DT contoured as an isomesh electron density
surface (omit map) contoured at 1.0σ. The position of the V190W mutation
used for the protein interference method is indicated. c Individual atomic
scores within the cooperativity binding network. The score is assigned
according to an increasing rank, starting with gray (neutral), blue/purple
(moderate), and red (relevant).
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highest sequence identity (34%) followed by Bacillus antracis
(28%), Haemophilus influenzae (23%), Staphylococcus aureus
(22%), and lastly Leishmania major (21%). Eighteen identical
residues (G8, G10, L30, D32, G40, D71, G84, D89, L90, N94,
P120, L146, S227, and A233 with D147, R150, R87, and N119)
cluster at the N-terminal cofactor binding domain (Rossmann-
fold). Five of these (H174, R150, R87, R81, and D147) are
involved in the catalytic mechanism where the three arginines
interact with the carboxylates groups of the substrate (malate
or oxaloacetate) through ionic contacts38. Table 2 summarizes
the sequence and surface analysis. Overall, the three indepen-
dent oligomeric interfaces of PfMDH possess a buried solvent
accessible surface area of 3481 Å2. Furthermore, as shown in
Supplementary Fig. 2, five of these interface interactions are
specific as they involve residues not strictly conserved in
PfLDH or in the MDH of H. sapiens, B. anthracis, Trypano-
soma cruzi and Brucella abortus (V169, N188, V190, F195, and
M200) and, only two residues share similar physiochemical
properties with other MDHs (V161 and L250). The AD
interface has a relatively small area (361 Å2) and accounts only
for 2.5% of the total buried surface area. In contrast, the AB
and AC interfaces represent the key contact surface for the
oligomerization (1811 and 1309 Å2, respectively) and are
essential for the biological activity in vitro20. In comparison
with the other six homologs, the interface residues are less
conserved than those of the active site (20%). Like the AD
interface, the AC contains no identical residues, however, it
accounts for higher buried ASA than the former, making it an
attractive target for structure-based drug design. PISA analysis
shows that upon ligand binding the guanidine side chain of
R183 from chain C loses one salt bridge with the E194 of chain
A. Similarly, contacts between K198 and E164 both in common
with the citrate and NADH bound form are lost as well as
between K228 from chain C and E164 of chain A. These data
suggest that 4DT most likely interferes with correct orientation
of intra-oligomeric contacts.
Fig. 3 Apo (green cartoons), citrate-liganded (orange cartoons, PDB ID:5NFR)20 and 4DT bound (purple cartoons) structures of PfMDH. a A close-up
view of the active site loop in close proximity to the NAD binding site. Pairwise Cα distances are expressed in Å and represented as red dotted lines while
loop amino acids as lines. b–e Side chain rearrangements of the interface residues involved in the formation of 4DT binding site (sticks representations).
f Close-up view displaying the lifting of the active site loop and distancing of R81 (stick representation) with consequent loss of one ionic interaction
depicted as red dotted lines.
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4DT derivative screening. In order to explore the
structure–activity relationships of the parental scaffold of 4DT,
we purchased new compounds from vendors with a higher
electron-withdrawing effect than fluorine (i.e., nitrile and tri-
fluoromethyl groups), atomic radius (i.e., chlorine and bromine),
and steric effect (i.e., isopropyl). In some cases, the amine group
was either replaced with a carboxylic acid or the whole thiazole
ring with isoxazole, pyrazole, and thiadiazole. The results of our
experiments are presented in Fig. 4 while the ANOVA summary
is in Supplementary Table 3. The enzyme activity in the presence
of compounds 7a (23%) and 4b (20%) was significantly reduced
in comparison with the control, followed by compounds 5a (52%)
and 5b (53%). In addition, enzyme activity measured in the
presence of compounds 1a (62%), 1b (60%), 2b (65%), 4a (65%),
and 9a (51%) resulted in a reduction of PfMDH activity with
similar statistical significance (Supplementary Table 4). Only
compound 6b showed no statistical difference with the control.
Finally, precipitation of compound was observed for the para-
isopropyl (compound 10a), para-nitro (compound 2a), meta-
trifluoro (compound 8a), and para-bromo (compound 6a) deri-
vatives, most likely due to their low solubility in the buffer.
The low aqueous solubility of this series of compounds makes the
measurement of an accurate IC50 curve extremely challenging and
the presented reduction in activity should not be used to draw
conclusions on the relative inhibitory properties of the
compounds.
Thermal destabilization of 4DT derivatives. Thermal shift assay
(TSA) experiments showed an overall decreased thermal stability
of PfMDH. The molecule with a trifluoromethyl group in meta
position (Tm= 48.0 ± 1.0 °C) (Supplementary Fig. 3a) displayed a
statistically significant decrease compared with control (ΔTm=
−10 °C), suggesting that bulky functional groups can thermically
destabilize in a more efficient manner the protein as a result of
the steric effect at the PfMDH A/C interface. In contrast, as can
be seen in Supplementary Fig. 3b, c, the presence of the com-
pounds 4PA (Tm= 55.0 ± 0.2 °C) as well as its substituted
dimethyl derivative (Tm= 54.0 ± 0.2 °C) shows a decrease in
melting temperature of ΔTm=−3.0 °C and −4.0 °C, respectively
with no statistical difference from the control (Tm= 58.0 ± 0.3 °C)
(Supplementary Table 7).
Table 2 Surface analysis with PISA online server60 and sequence conservation across another malate dehydrogenase.
Number of residues 313
Identical 18 (5.7%)
Similar 52 (16.6%)
Active site residues 5
Identical 4 (80%)
Similar 1 (20%)
Interface AB AC AD Total
Residues 50 38 12 100
Identical 8 (16.0%) 0 0 8 (8.0%)
Similar 3 (6.0%) 7 (18.4%) 1 (8.3%) 11 (11.0%)
Not identical 39 (78.0%) 31 (81.6%) 11 (91.7%) 81 (81.0%)
Total ASA per monomer (Å2) 14,577
Buried ASA (Å2) 1811 (12.4%) 1309 (9.0%) 361 (2.5%) 3481 (23.9%)
Fig. 4 Dot plot inhibition of the 4DT derivatives vs. control (DMSO). Data are represented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 (n= 2
biologically independent experiments).
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Inhibitory and allosteric nature of 4PA. Experiments using 4PA
and performed in 5 mM L-malate revealed an IC50 value of 1.17 ±
0.04 mM (Fig. 5a, Supplementary Table 5). We observed turbidity
in the treated wells, most likely due to the low compound solu-
bility in the chosen buffer. Nevertheless, lower doses show the
disappearance of the effect, thus confirming the inhibitory nature
of 4PA. Based on this observation, we decreased the 4PA con-
centration. Subsequent kinetic measurements were performed
with PfMDH, varying the concentration of malate as the reaction
substrate in optimal assay conditions. The results are presented in
Fig. 5b and the model fitting summary in Supplementary Table 6.
In comparison to other reports, the control showed substrate
inhibition at the highest malate concentration (10 mM)24. Thus,
the oxidation of the malate curve was fitted using a substrate
inhibition model, resulting in a calculated Vmax of 967.8 ± 99.0 U
mg−1 and Km of 0.4 ± 0.1 mM. The same experiment was per-
formed in the presence of 63 μM 4PA which showed a decreased
Vmax of 645.7 ± 29.0 Umg−1 and Km of 0.2 ± 0.0 mM. Similarly,
doubling the concentration of 4PA to 125 μM led to Vmax of
630.2 ± 28.5 Umg−1 and Km of 0.2 ± 0.003 mM. Moreover, our
data indicate a decrease in substrate binding affinity induced by
the presence of 4PA with a calculated Ki of 12.5 ± 4.2 mM in the
control and Ki 63.0 ± 31.8 mM and 72.9 ± 41.9 mM in the pre-
sence of 63 and 125 μM 4DT, respectively. Taken together, these
data indicate a non-competitive mechanism of the inhibition of
4PA and a simultaneous decrease in the binding affinity for
malate.
Small-angle X-ray scattering. In order to further validate the
interference effect at the oligomeric interface, we performed
small-angle X-ray scattering (SAXS) experiments. SAXS is rou-
tinely used to determine the oligomeric states of proteins in
solution due to the noninvasive character of this technique. As
SAXS detects even nanoscale electron density fluctuations it can
be employed to determine the tetrameric and dimeric states of
malate dehydrogenase. Only the 4DT derivatives that previously
showed no aggregation in DLS, i.e., 2a and 6a, were tested with
SAXS since aggregated protein samples give SAXS signals that
cannot be interpreted. As can be seen in Supplementary Fig. 4a, b,
the samples of PfMDH apoprotein and in complex with com-
pound 2a appear to be tetramers of ca. 110 kDa (expected
molecular weight calculated from the sequence would be 136
kDa), and the radius of gyration of 33.8 Å (Supplementary
Table 8). Only the complex with compound 6a seems slightly
more open (Supplementary Fig. 4c), with an Rg of 36.4 Å. Finally,
Fig. 6 shows that the three scattering curves fit the crystal
structures of PfMDH in the absence and presence of compounds
2a and 6a well with the goodness-of-fit below 1.0 as calculated
using crysol software39, thus suggesting a good correlation
between crystal structures and complexes in a solution.
Discussion
MDH is involved in energy metabolism, pyrimidine biosynthesis
as well as supplying the TCA cycle, sustaining abnormal cell
growth like in cancer or parasite infection like in P. falciparum.
Hence, the HsMDH1 and HsMDH2 antagonists were synthesized
(Supplementary Table 1) for cancer, or substrate/cofactor analogs,
i.e., oxamic acid derivatives for PfLDH (Supplementary Table 2)
and PfMDH for parasitic diseases. Unfortunately, they lack on-
target selectivity, since they bind a strongly conserved active site.
Allosteric modulation of this class of enzymes may allow an
improved selectivity between host and pathogen MDHs, as well as
between MDHs and LDHs, thus leading to better-tolerated
treatments.
PfMDH represents a model protein well studied by us both
in vitro20 and in vivo21. The surface analysis results show that
16% of AB interface residues are identical across six exemplifi-
cative species (i.e., H. influenzae, B. antracis, H.sapiens, L. major,
S. aureus, B. antracis) and E. coli dimeric MDH (29% sequence
identity)20. In contrast, the AC interface has a slightly higher
number of non-identical residues than AB (81.6% vs. 78%), but
no identical ones. These data indicate that, firstly, the AC inter-
face could be targeted by small molecules with potentially
improved specificity and, secondly, each MDH possesses a unique
AC/BD network of contacts. Moreover, the hypothesis of the
existence of an allosteric site has been advanced by mutagenic
studies, yet remained cryptic until now32. We have screened for
mutations on this interface and could only identify the V190W as
a mutation that resulted in a soluble dimer that retained the active
site architecture. For example, the V190I mutation resulted in an
insoluble construct, and mutations at other points of the dimeric
interface did not have the desired effect of impacting the oligo-
meric state of PfMDH. Therefore, we engineered a soluble mutant
(V190W) that does not exist in nature, with a solvent-exposed
oligomeric surface for comparative analysis of hits from NMR
screening.
Our joint experiments based on STD-NMR, X-ray, MST, and
TSA led us to elucidate the binding pocket of 4DT, a molecule
with potential drug-like properties but still with a weak Kd that
nevertheless is typical of fragments40. We show that 4DT binds
with a Kd of 99 μM to wild-type PfMDH in an MST assay per-
formed using 50 nM PfMDH and a concentration range of 4DT
from 240 nM to 4 mM. However, 4DT could not be seen to bind
to the same protein under the STD-NMR conditions at a 100-fold
molar excess. However, the concentration of protein used in the
STD-NMR experiments was 10 μM. This clearly shows the
essential problem in high-throughput fragment screening, in that
Fig. 5 Study of the biological response of PfMDH in the presence of 4PA. a Left part: dose/response inhibition of PfMDH. Data are presented as mean ±
SEM (n= 3 biologically independent experiments). b Kinetics studies of two different concentrations of 4PA vs. control (DMSO) using the substrate
inhibition model. Experiments were carried in the same plate. y-Axis shows enzyme activity expressed as U= μmol of NAD+ reduced per minute by 1.0 mg
of PfMDH. Data are presented as mean ± SEM (n= 3 biologically independent experiments).
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differing methods often show widely differing Kds. However, we
believe that our STD-NMR approach allowed us to identify dif-
ferential binders, and thereby identify 4DT as a molecule that
binds to the oligomeric interface exposed by the V190W
mutation.
The allosteric site is located approximately 35 Å away from the
malate/cofactor binding site. In this pocket formed 4DT interacts
through van der Waals and π-stacking interactions with the
surrounding amino acids, including the key residue V190. Upon
binding to 4DT, other key residues, for example, L250 and F284,
undergo clear structural rearrangements to allocate 4DT with the
benzene ring facing the oligomeric interface. Such orientation is
in accordance with the NMR spectrum as the high peak inten-
sities can be seen in the aromatic protons. Distal from the
allosteric site, we furthermore observed that the active site
Q80–L90 loop remains in the open state, ready to allocate a
substrate and cofactor molecule. During the refinement, no citrate
atoms were modeled due to a lack of consistent electron density,
despite the presence of 1.4 M citrate in the reservoir solution. This
evidence relates to its effect of protein stabilization as shown by
our co-crystal (PDB: 5NFR) and subsequentially increase in ΔTm
using TSA20, most likely due to the formation of three ionic
bonds, two of them from the active site loop, e.g., R81 and R87,
and R150. Thereby, 4DT might reduce the binding affinity
towards malate but more generally towards other similar car-
boxylic acids such as citrate.
At this point, it is tempting to speculate that the binding may
well result from the ligand-dependent conformational selection.
Due to the small size of the fragments, we cannot exclude the
possibility for non-specific binding at other locations of PfMDH.
As these fragments are highly hydrophobic in nature it is not
unreasonable to suggest also that they may negatively impact the
protein fold, without interfering at the dimer interface. To that
respect, it should be noticed that all our TSA experiments display
a negative ΔTm with indeed no statistical difference from the
control as for 4DT, 4PA, and compound 5a. However, only the
compound carrying the bulkiest functional group displayed a
significant difference suggesting interference with intraoligomeric
contacts resembling the indole ring but still not yet strong enough
to produce the same effect as the mutation.
To further explore this hypothesis, we have screened 4DT
analogs and conducted more in-depth studies with 4PA, a more
tractable homolog of 4DT. 4PA and 4DT share the benzene and
thiazole rings as this system concentrates the highest cooperative
binding score. In addition, these molecules differ only by two
fluorines whose van der Waals radius (1.47 Å) is similar to that of
a hydrogen atom (1.20 Å). This makes their dimensions very
similar but at the cost of a decreased water solubility for 4DT.
Moreover, this compound has been screened for the drug dis-
covery of highly profitable antiviral and anticancer targets like
HIV-1 nucleocapsid41 and the TIR domain of human MyD8842.
Thus, our choice is motivated as 4PA has proved to be slightly
more soluble than 4DT and, due to its structural similarity with
4DT, it served as a model molecule to confirm the allosteric
nature of the pocket we elucidated. 4PA displayed both
dose–response effect and a Ki decrease by 6–5× fold in presence
of 125 and 63 μM of compounds. Taken together, these data
indicate the presence of a cryptic allosteric site in PfMDH where
4DT analog may bind in an inhibitory noncompetitive fashion.
These experiments on 4DT certainly cannot exclude a possible
interaction with HsMDH1 and HsMDH2 for which it would be
necessary to conduct a selectivity study. However, in both cases,
the cooperativity binding scores are lower than PfMDH (9.5),
meaning that binding to the AC/BD interfaces benefits from the
local network of interactions. Besides, we found only 16 crystal
structures corresponding to the desired homodimer quaternary
structure and none of these is co-crystallized with inhibitors
similar to 4DT. This implies that our docking models need to be
interpreted cautiously since they cannot be validated with a co-
crystallized reference. In that respect, further kinetics experiments
should be carried out in the future to better understand the 4DT
mechanism of action with both human isoforms.
With the identification of 4DT, a number of 4DT derivatives
were screened, and interestingly these did not show the same
enzyme activity. For example, in compound 1b the single removal
of a fluorine atom per se does not impact the oxidative activity of
PfMDH in the assay. This effect could be traced to the Van der
Waals radius of fluorine (1.40 Å), which is similar to that of
hydrogen (1.20 Å). Consequently, its substitution with one
hydrogen atom does not generate a steric surface at the AC
interface. In contrast, replacement with two chlorides of larger
Van der Waals radius (1.75 Å) than fluorine significantly impacts
enzymatic activity, as shown by derivative 7a. Nevertheless, we
are aware that the diversity of the compound library is insufficient
for establishing structure–function relationships models. How-
ever, we believe that this evidence suggests bulky functional
groups should be preferred for providing more interfering sur-
faces. With its higher Van der Waals radius (1.85 Å), the para-
bromo derivative (6b) is an exemplificative case that strengthens
the latter hypothesis, as shown by SAXS. Such technique is a great
validation technique and as such, it was initially used to check for
artificial contacts in the crystal structure of PfMDH as mea-
surements in SAXS are performed in native conditions (no crystal
formation, buffer of a choice). As shown in data from software
Fig. 6 Study of oligomeric fluctuations of PfMDH by characterization of its SAXS profile. The overlay of scattering profiles from PfMDH apoprotein
(blue), PfMDH in complex with compound 6a (orange) and compound 2a (green).
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Crysol, the goodness of fit between SAXS measurement of apo
PfMDH and putative one calculated from atom positions in the
crystal overlap nicely. Next, we suspected inhibitors to disrupt the
quaternary structure of PfMDH into dimers, which SAXS would
in theory very nicely follow. It turned out, though, that many of
the samples were heavily aggregated preventing SAXS measure-
ments, except for compounds 2a and 6a. Here, we found out that
compound 6a opens up the structure of PfMDH as reflected by a
higher value for the radius of gyration 36.4 Å compared to 33.7 Å
for apo PfMDH meaning that it did not dissociate the complex of
4 PfMDH subunits, but located itself in the middle causing them
to distance themselves from each other a bit, which is fascinating
given the small size of the compound. The strength of this study
lies in the fact that compound 6a was not forced into the structure
of PfMDH due to crystal lattice formation or soaking of the
crystal, but consequently bound all (or almost all) available
PfMDH under native buffer conditions. Furthermore, we showed
that SAXS was able to detect compounds otherwise discarded on
the sole basis of their biological activity as exemplified by com-
pound 6b.
In summary, our data pave the way for downstream develop-
ment of more selective molecules by utilizing the oligomeric
interfaces showing higher species sequence divergence than the
MDH active site by using fragment-based screening techniques
and activity assay.
Materials and methods
Recombinant protein expression and purification. To obtain the V190W MDH
mutant, site-directed mutagenesis was performed as described by Lunev et al.20.
The full-length WT PfMDH gene was cloned into pETM-13, embedding addi-
tional non-cleavable amino acids AAALEHHHHHH at the C-terminus. The
construct was verified by automated sequencing (Sanger) (Supporting Infor-
mation). Subsequently, E. coli Rosetta 2 (DE3) pLysS (Novagen) were trans-
formed with a pETM-13 vector bearing the PfMDH gene for recombinant
protein production. Cells were grown in TB media supplemented with
50 mg ml−1 kanamycin and 35 mg ml−1 chloramphenicol. An overnight pre-
culture grown at 310 K was used to inoculate the main production culture
(supplemented by 0.5% glucose to prevent leaky expression), which was grown at
310 K to an OD 600 of 0.6–0.8. Subsequently, enzyme expression was induced
with 1 mM isopropyl-β-D-thiogalactopyranoside, and the cells were incubated
for 16–18 h at 310 K. The cells were harvested by centrifugation at 5000 rpm for
30 min at 4 C and resuspended in lysis buffer (50 mM Tris-HCl, 300 mM NaCl,
30 mM imidazole, pH 8.0) protease inhibitors (Complete Mini EDTA-free,
Roche Applied Science) and a spatula tip of lysozyme. After sonication on ice,
the lysate was centrifuged for 45 min at 18,000 rpm and the supernatant was
passed through a 0.45 μm filter (Whatman) to remove traces of unlysed cells and
aggregates. The clarified cell lysate was purified by immobilized metal ion affi-
nity chromatography with buffer A (50 mM Tris-HCl, 300 mM NaCl, pH 8.0)
and buffer B (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 500 mM imidazole) over a
5 mL His-Trap HP column (GE Healthcare). Bound protein was eluted from the
column at 125–150 mM imidazole. The sample obtained after Ni-NTA pur-
ification was diluted 6-fold with 50 mM Tris-HCl pH 8.0 and loaded on a 5 ml
Cation Exchange column (GE Healthcare). The protein was eluted from the
column by a linear gradient ranging from 50 mM to 1 M NaCl. Finally, the
sample was concentrated and injected onto a HiLoad 16/600 Superdex 200
column (GE Healthcare), previously equilibrated in buffer C (100 mM Na-
phosphate buffer pH 7.4 and 400 mM NaCl). The final yield of pure protein from
1 L culture was typically between 6 and 10 mg ml−1 The purity of the protein was
assessed by sodium dodecyl sulfate gel as better than 98%.
NMR experiments. NMR spectra were acquired on Bruker Avance III (600MHz)
spectrometer at 300 K, equipped with a triple resonance cryoprobe head and an
automated SampleJet sample changer. The samples for STD experiments were
prepared in 100 mM Na-phosphate pH 7.4, 400 mM NaCl and spectra were
recorded in water with 1:100-fold excess of the fragment (dissolved in DMSO at
100 mM) in an additional 10% (v/v) D2O to provide a lock signal. Final protein and
ligand concentrations were 10 μM and 1 mM, respectively. Selective saturation of
the protein resonances (on resonance spectrum) was performed by irradiating at
0.5 ppm using a series of Eburp2.1000-shaped 90 pulses (50 ms, 1 ms delay between
pulses) for a total saturation time of 2.0 s. For the reference spectrum (off-reso-
nance), the samples were irradiated at −10 ppm. On- and off-resonance scans were
subtracted using phase cycling. The fragment library screening was performed by
testing 300 mixtures containing five fragments each initially. Mixtures that yielded
positive STD signals were selected and deconvolved, i.e., fragments that formed
“active” mixtures were tested separately. Spectra were analyzed with TopSpin®
software, 4.0
Microscale thermophoresis. A Nanotemper MonolithNT.115 instrument (Nano-
temper Technologies, GmbH) was used to quantify ligand/protein interactions.
Purified PfMDH was labeled using the Red-NHS Monolith Protein Labeling Kit
according to the manufacturer’s protocol43. All reactions were performed in 100
mM Na-phosphate buffer pH 7.4, 400 mM NaCl, 0.05% Tween-20 in standard
capillaries (Nanotemper Technologies GmbH). The ligand was 2× fold diluted
starting from 4mM as the highest concentration; the final protein concentration
was 50 nM. All samples were incubated with compounds for about 1 h at room
temperature followed by centrifugation at 18,000 rpm (Eppendorf Centrifuge
5415R) before loading into capillaries. Measurement was performed in triplicate at
40% LED intensity and 40% MST power. The Kd model was employed to deter-
mine the binding constant using the software MO.Affinity Analysis v2.3 while data
collection was performed with MO.Control 2 (Nano-temper
Technologies, GmbH).
Thermal shift assay. TSA is a rapid and economical biophysical technique for
protein folding, buffer optimization and it has been revealed a flexible method
for high thought screening in early stage drug discovery44 and fragment-based
drug design45. The TSA experiment was conducted in a BioRad CSX 96 (Biorad).
Each reaction consisted of 1 mM of compound (100 mM stock in 100% (v/v)
DMSO) and 10 μM PfMDH in 100 mM Na–phosphate buffer pH 7.4, 400 mM
NaCl, and 10× Sypro Orange (Invitrogen) for a total volume of 100 μl. Control
experiments were performed with 1% (v/v) DMSO. Inflection points were
determined using BioRad CFX96™ control software. Generally, a temperature
increase of over 1 °C is interpreted as a result of the stabilization of the protein-
ligand interaction. On the contrary, a negative shift is considered a destabili-
zation caused by the fragment.
Crystallization, X-ray data collection, and processing. Initial efforts focused on
the crystallization conditions described in the literature by Wrenger et al.33. Initial
hits grew in 22% (w/v) PEG 3350, 4 °C, at a protein concentration of 10 mgml−1
after 2 days. The buffer was supplemented with 500 μM NADH since it increases
the thermal stability of the protein20. Streak seeding experiments were used to
reproduce a large number of crystals in different buffer conditions, though not of
sufficient quality for data collection. The crystals were subsequentially optimized by
screening the ratio of protein to reservoir solution (1.4 M trisodium citrate, 100
mM Hepes pH 7.5) at 20 °C. First hits appeared in 2–3 days and reached maximum
dimension after one week at 10 mgml−1 concentration and a 1:3 ratio of protein:
reservoir solution. To generate the complex structure the crystals were then soaked
with 2.5 mM ligand for 2 h at 20 °C, transferred into a cryoprotective solution made
of reservoir solution supplemented with 30% w/v ethylene glycol, and flash-cooled
in nitrogen steam. A dataset was collected in-house, using a D8 Venture dif-
fractometer (BRUKER) equipped with a PHOTON II detector, at 100 K. The
crystal diffracted to 2.1 Å resolution and belongs to space group P212121 with four
molecules in the asymmetric unit, corresponding to one functional tetramer, the
solvent content of ~43%, and a mosaicity of 0.3°. The data were processed using the
program XDS46, reduced and scaled using XSCALE46, and amplitudes were cal-
culated using CTRUNCATE47. The structure was solved using molecular repla-
cement (MOLREP48) with 5NFR as a search model. Refinement was carried out
using REFMAC549 applying TLS restraints. Between refinement cycles, the model
was subjected to manual rebuilding using COOT. Water molecules have been
added using the standard procedures within the ARP/WARP suite50. The quality of
the refined structure was assessed using the program MOLPROBITY51. Coordi-
nates and structure factors have been deposited at the PDB under the accession
code 6R8G (PfMDH in complex with 4DT and NADH) and 6Y91 (PfMDH in
complex with NADH).
Activity assay and data analysis. The oxidation of malate to oxaloacetate was
assayed spectrophotometrically in flat-bottomed Corning 96-well microplates in
a total volume of 250.0 µl in 50 mM glycine buffer pH 10.224 with an additional
400 mM NaCl for protein stability. The increase of absorbance at 340 nm was
recorded in kinetic mode using a Tecan Spark multimode microplate reader at
298 K. A mastermix of 50 mM NAD+ and 44 μM PfMDH was used for both the
screening and kinetics experiments. The final concentration of protein and
cofactor were 50 and 3 mM, respectively. Positive control groups were set
(absence of compound) in the same plate as the treated group. The absorbance
from the background noise was subtracted from the data and then a linear
regression model was employed in order to get the line slope from the first 5 min
of the reaction. The percentage of enzymatic activity has been calculated as
described by Eq. (1)
enzyme activityð%Þ ¼ slope treated
slope positive control
*100 ð1Þ
Enzymatic assay and kinetics experiment. While the fragment initially dis-
covered was 4-(3,4-difluorophenyl) thiazol-2-amine, we decided to perform
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enzymatic and kinetic assays using a similar substructure 4-phenylthiazol-2-
amine. 2× fold dilutions from a 200 mM stock solution of the compound in
100% DMSO was prepared for dose–response experiments. 3.3 µL of
compound (DMSO in the case of positive control) were mixed with 233.9 µL
mastermix of WT PfMDH previously incubated with 3 mM NAD+ using a
multichannel pipette. The final conditions tested were a maximum of 2.5 mM of
4PA at 1.32% (v/v) final DMSO concentration. The microplate was incubated
for 15 min at 25.35 °C and the reaction started with the addition of 13.0 µL of 5
mM L-malate.
Kinetics experiments were performed by mixing 1.3 µL of compound stock
solutions from 12.5 and 25 mM of 4PA in 100% DMSO with 223.8 µL mastermix
of PfMDH previously incubated in ice with 3 mM NAD+ for 30 min. Final
tested concentrations of 4PA were 125.0 and 62.5 μM and 0.5% (v/v) DMSO.
Subsequently, eight concentrations of L-malate were prepared apart by 2× fold
serial dilution from a 100 mM stock in assay buffer at pH 10.2. After 1 h of
incubation at 26 °C, the reaction was started by the addition of 25.0 µL L-malate
(5 mM final concentration) with a multichannel pipette. The µmol of NADH
produced per minute was extrapolated from the calibration curve and then
divided by the corresponding milligrams of the enzyme (0.00175 mg). Kinetic
constants Km (mM) and Vmax (U * mg−1) and Ki (mM) were quantified with
GraphPad Prism version 8.0 according to the substrate inhibition Eq. (2)52.
Y ¼ V*maxX=ðKm þ X*ð1þ X=KiÞÞ ð2Þ
All measurements were performed in triplicate.
Screening of 4-phenylthiazol-2-amine derivatives. 1.3 µL of derivatives of 4-
phenylthiazol-2-amine in 100% DMSO were mixed with 237.7 µL of a mastermix
of WT PfMDH previously incubated with NAD+. The final compound con-
centration used in this screening was 500 µM in the presence of 0.5% (v/v) DMSO.
The microplate was sealed with silver foil for 1-h incubation at 25–35 °C. Finally,
reactions in both the samples and control wells were started upon the addition of
13.0 µL of 5 mM malate). At the end of the experiments, the reaction of the plate
was spectrophotometrically assayed at 600 nm in order to identify turbidity due to
the low solubility of the compound. All measurements were performed in
duplicate.
Statistics and reproducibility. Unless otherwise stated, data were presented as the
mean ± SEM in triplicate. The normality tests were done with the Anderson-
Darling, D’Agostino, Shapiro–Wilk, and Kolmogorov–Smirnov methods. Pairwise
p values of 4DT derivative screening were calculated using ordinary one-way
ANOVA with Dunnet correction with *p < 0.05, **p < 0.01, ***p < 0.001 indicat-
ing the statistical significance. TSA statistics were derived with a non-parametric
Kruskal Wallis test. Data were prepared with Microsoft Excel and Graph Pad Prism
software (v 8.0).
Computational analysis. Molecular interactions as well as the representation of
the bond length and the scoring of the cooperativity binding network was gener-
ated with Scorpion53. Pictures were rendered with PyMol (The PyMOL Molecular
Graphics System, Version 2.0 Schrödinger, LLC). The compound 4DT was mini-
mized using OpenBabel54 software and docked with AutoDock Vina integrated
into PyRx55 using as a receptor either the human mitochondrial HsMDH2 (PDB:
4WLV) or the cytoplasmic homology using pig heart MDH1 as a template (PDB:
4MDH) (Supplementary Methods 1). Homology modeling was performed with
SWISS-MODEL (Supplementary Methods 2)56. The search volume was composed
of the whole protein.
SAXS experiments. X-ray scattering experiments were performed using the
laboratory SAXS system Xeuss 2.0 (XENOCS, Grenoble, France) equipped with a
MetalJet D2 microfocus X-ray generator (0.134 nm wavelength). The protein
solution at a concentration of 2.49 mgml−1 was mixed with 4PA derivatives at a
concentration of 1 mM, incubated for 1 h at room temperature, and spun at 16,000
rpm (Eppendorf Centrifuge 5415R) to remove any potential aggregates prior to
injection into the low-noise liquid sample cell. SAXS data were collected in
3–4 subsequent 10 min long frames using a Pilatus3R 1M hybrid photon counting
detector (Dectris, Switzerland). Data reduction and buffer subtraction procedures
were performed using the Foxtrot package. Scattering profiles were assessed for
radiation-damaged and averaged. Structural parameters were calculated in Primus
from the ATSAS package57. The distance distribution function was calculated using
GNOM58.
Dynamic light scattering. Measurements were performed on Litesizer 500 (Anton
Paar). Samples were incubated with the highest concentrations of compounds for 2
h at room temperature. Prior to measurements, samples were spun for 5 min at
16,000 rpm (Eppendorf Centrifuge 5415R) to remove aggregates.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The SAXS data have been deposited in the SASBDB59 under the access codes SASDLQ2
(PfMDH L-lactate dehydrogenase, apo), SASDLR2 (PfMDH L-lactate dehydrogenase
bound to inhibitor 2a), and SASDLS2 (PfMDH L-lactate dehydrogenase bound to
inhibitor 6a). The structures are currently on hold and will be released upon publication.
Coordinates and structure factors have been deposited at the PDB under the accession
code 6R8G (PfMDH in complex with 4DT and NADH) and 6Y91 (PfMDH in complex
with NADH). The authors confirm that the data supporting the findings of this study are
available within the article [and/or] its supplementary materials. Supplementary Data 1:
MST data processing (.moc), validation report (.pdf) and raw data used for Fig. 1 (.xlsx).
Supplementary Data 2: raw data used for Fig. 1 (.xlsx). Supplementary Data 3.xlsx: PISA
alignment and interfaces analysis. Supplementary Data 4.csv: thermal shift assay raw
data. Supplementary Data 5.pdf: validation report for Crystal structure of malate
dehydrogenase from Plasmodium falciparum incomplex with 4-(3,4-difluorophenyl)
thiazol-2-amine (PDB ID: 6R8G). Supplementary Data 6.pdf: validation report for the
Crystal structure of malate dehydrogenase from Plasmodium falciparum in complex with
NADH (PDB ID: 6Y91). Supplementary Data 7.xlsx: Statistics and data processing for
4DT derivatives. Supplementary Data 8.xlsx: Statistics and data processing for 4PA
dose–response experiment. Supplementary Data 9.xlsx: Statistics and data processing for
4PA kinetics experiments. Supplementary Data 10.doc: C-terminal His-tagged PfMDH
WT sequencing data and primary sequence.
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